| [1] |
Silberstein EB.Teletherapy and radiopharmaceuticaltherapy of painful bone metastases.Semin Nucl Med,2005,35(2):152-158.
|
| [2] |
Finlay IG,Mason MD,Shelley M,Radioisotopes for the palliation of metastatic bone cancer:a systematic review.Lancet Oncol,2005,6(6):392-400.
|
| [3] |
Kvinnsland Y,Bruland O,Moe L,et al.A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section withadigital silicon detector:application to a study of 89SrCl2 and 153 Sm-EDTMP in a dog with spontaneous osteosarcoma.Eur J Nucl Med Mol Imaging,2002,29(2):191-197.
|
| [4] |
Falkmer U,Jarhult J,Wersau P,et al.Systematic overview of radiation therapy effects in skeletal metastases.Acta Oncol,2003,42(5-6):620-633.
|
| [5] |
Deng HF,Zhang XY,Tan TZ,et al.Treatment of metastatic bone pain with Strontium-89.J Nucl Med,2003,44(5):413.
|
| [6] |
范义湘,罗荣成,李贵平,等.骨显像联合B-AKP测定评价89Sr治疗前列腺癌骨转移疗效.中华男科学,2004,10(3):178-181.
|
| [7] |
Zyskowski A,Lamb D,Morum P,et al.Stronlium-89 treatment for prostate cancer bone metastases,does a prostate-specific antigen response predict for improved survival?.Australas Radiol,2001,45(1):39-42.
|
| [8] |
Soerdjbalie-Maikoe V,Pelger RC,Lyckiama â Nijeholt GA,et al.Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.Eur J Nucl Med Mol Imaging,2002,29(4):494-498.
|
| [9] |
Oosterhof GO,Roberts JT,de Reijke TM,et al.Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer:a phase III study of the European Organisation for Research and Treatment of Cancer,Genitourinary Group.Eur Urol,2003,44(5):519-526.
|
| [10] |
Sciuto R,Festa A,Rea S,et al.Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.J Nucl Med,2002,43(1):79-86.
|
| [11] |
Pagliaro LC,Delpassand ES,Williams D,et al.A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases.Cancer,2003,97(12):2988-2994.
|